{"id":470,"date":"2026-01-19T12:39:08","date_gmt":"2026-01-19T11:39:08","guid":{"rendered":"https:\/\/ced-studienzentrum.berlin\/2026\/01\/19\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/"},"modified":"2026-02-03T11:03:06","modified_gmt":"2026-02-03T10:03:06","slug":"crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab","status":"publish","type":"post","link":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/","title":{"rendered":"Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab)"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”target group” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”|auto|-1px|auto|false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.27.5″ _module_preset=”default” title_text_color=”#10344C” title_font_size=”45px” custom_margin=”||15px|||” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}”]Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn’s disease and compares it with the single application. The aim is to determine which therapy works best after 48 weeks. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn’s disease and compares it with the single application. The aim is to determine which therapy works best after 48 weeks.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[38,41],"tags":[],"class_list":["post-470","post","type-post","status-publish","format-standard","hentry","category-for-participants","category-ongoing"],"yoast_head":"\nCrohn's disease: DUET-CD study (combination of guselkumab and golimumab) - CED Studienzentrum Karlshorst<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crohn's disease: DUET-CD study (combination of guselkumab and golimumab) - CED Studienzentrum Karlshorst\" \/>\n<meta property=\"og:description\" content=\"Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn's disease and compares it with the single application. The aim is to determine which therapy works best after 48 weeks.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/\" \/>\n<meta property=\"og:site_name\" content=\"CED Studienzentrum Karlshorst\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T11:39:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T10:03:06+00:00\" \/>\n<meta name=\"author\" content=\"Pauline Lauterbach\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pauline Lauterbach\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/\"},\"author\":{\"name\":\"Pauline Lauterbach\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"headline\":\"Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab)\",\"datePublished\":\"2026-01-19T11:39:08+00:00\",\"dateModified\":\"2026-02-03T10:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/\"},\"wordCount\":256,\"articleSection\":[\"For participants\",\"Ongoing\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/\",\"url\":\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/\",\"name\":\"Crohn's disease: DUET-CD study (combination of guselkumab and golimumab) - CED Studienzentrum Karlshorst\",\"isPartOf\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#website\"},\"datePublished\":\"2026-01-19T11:39:08+00:00\",\"dateModified\":\"2026-02-03T10:03:06+00:00\",\"author\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"breadcrumb\":{\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#website\",\"url\":\"https:\/\/ced-studienzentrum.berlin\/en\/\",\"name\":\"CED Studienzentrum Karlshorst\",\"description\":\"Dr. Thomas Brunk\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb\",\"name\":\"Pauline Lauterbach\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"caption\":\"Pauline Lauterbach\"},\"url\":\"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crohn's disease: DUET-CD study (combination of guselkumab and golimumab) - CED Studienzentrum Karlshorst","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/","og_locale":"en_US","og_type":"article","og_title":"Crohn's disease: DUET-CD study (combination of guselkumab and golimumab) - CED Studienzentrum Karlshorst","og_description":"Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn's disease and compares it with the single application. The aim is to determine which therapy works best after 48 weeks.","og_url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/","og_site_name":"CED Studienzentrum Karlshorst","article_published_time":"2026-01-19T11:39:08+00:00","article_modified_time":"2026-02-03T10:03:06+00:00","author":"Pauline Lauterbach","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pauline Lauterbach","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/#article","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/"},"author":{"name":"Pauline Lauterbach","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"headline":"Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab)","datePublished":"2026-01-19T11:39:08+00:00","dateModified":"2026-02-03T10:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/"},"wordCount":256,"articleSection":["For participants","Ongoing"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/","url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/","name":"Crohn's disease: DUET-CD study (combination of guselkumab and golimumab) - CED Studienzentrum Karlshorst","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website"},"datePublished":"2026-01-19T11:39:08+00:00","dateModified":"2026-02-03T10:03:06+00:00","author":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"breadcrumb":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/"},{"@type":"ListItem","position":2,"name":"Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab)"}]},{"@type":"WebSite","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website","url":"https:\/\/ced-studienzentrum.berlin\/en\/","name":"CED Studienzentrum Karlshorst","description":"Dr. Thomas Brunk","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb","name":"Pauline Lauterbach","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","caption":"Pauline Lauterbach"},"url":"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/"}]}},"_links":{"self":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/comments?post=470"}],"version-history":[{"count":2,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/470\/revisions"}],"predecessor-version":[{"id":475,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/470\/revisions\/475"}],"wp:attachment":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/media?parent=470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/categories?post=470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/tags?post=470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}